Also, we did not validate prognostic specificity and sensitivity of MPMs in ccRCC patients from a real‐world cohort; thus, we presented prognostic value of MPMs in CRTAC and validate role of G6PC in > 1000 ccRCC patients from TCGA, CPTAC, RECA‐EU, HPA and FUSCC (validation cohort in China) cohorts. The gene discussed is G6PC1; the disease is nonpapillary renal cell carcinoma.